PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29545101-0	2018	Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.	1,2,3,4-tetrahydroisoquinoline	63-93	phosphodiesterase 4A	Homo sapiens	119-123	
31099559-2	2019	Aiming to find a novel PDE4 inhibitor acting as an effective, safe, and convenient therapeutic agent, we constructed a library consisting of berberine analogues, and compound 2 with a tetrahydroisoquinoline scaffold was identified as a novel and potent hit.	1,2,3,4-tetrahydroisoquinoline	184-206	phosphodiesterase 4A	Homo sapiens	23-27	
33218684-4	2021	In our previous work, we identified a series of novel PDE4 inhibitors with a tetrahydroisoquinoline scaffold through structure-based drug design, among which compound 1 showed moderate inhibition activity against PDE4.	1,2,3,4-tetrahydroisoquinoline	77-99	phosphodiesterase 4A	Homo sapiens	54-58	
33218684-4	2021	In our previous work, we identified a series of novel PDE4 inhibitors with a tetrahydroisoquinoline scaffold through structure-based drug design, among which compound 1 showed moderate inhibition activity against PDE4.	1,2,3,4-tetrahydroisoquinoline	77-99	phosphodiesterase 4A	Homo sapiens	213-217	
33218684-8	2021	Overall, our study provides a basis for further development of tetrahydroisoquinoline-based PDE4 inhibitors against psoriasis.	1,2,3,4-tetrahydroisoquinoline	63-85	phosphodiesterase 4A	Homo sapiens	92-96	
28888661-0	2017	Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.	1,2,3,4-tetrahydroisoquinoline	68-98	phosphodiesterase 4A	Homo sapiens	124-128	
26320621-0	2015	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.	1,2,3,4-tetrahydroisoquinoline	53-75	phosphodiesterase 4A	Homo sapiens	101-105